Immunomedics reports Phase I/II metastatic breast cancer data for sacituzumab govitecan

Immunomedics Inc. (NASDAQ:IMMU) said sacituzumab govitecan (IMMU-132) led to an overall response rate (ORR) of 31% in a cohort of 54 patients with estrogen receptor-positive, HER2-negative metastatic

Read the full 275 word article

User Sign In